PATENT CLAIM ANALYSIS

Application Number: 15970268
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "232800"]

Abstract:
Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.

Claim (Index 14):
The compound of  claim 1 , wherein the compound is of the formula, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.51515
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15499532', '15740462', '16320589', '15557703', '13662135']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7965650987343088
- 35 USC 102 Novelty (BERT): 0.6864494028939776
- Combined Prediction Score: 0.7855535291502757
- Mean Citation Score: 470.173268
- Max Citation Score: 770.49347
- Similarity Product: 669.2842535110915

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test